| Literature DB >> 32021862 |
Terenzio Cosio1, Sara Mazzilli1, Luca Bianchi1, Elena Campione1.
Abstract
Gefitinib is a multi-target tyrosine kinase inhibitor used for the treatment of non-small cell lung cancer. Papulo-pustular and/or paronychia, abnormalities in hair growth, itching, and dryness due to epidermal growth factor inhibitors - i.e., PRIDE Complex - are a common effect of tyrosine kinase inhibitors. We report a case of hair and eyebrow hyperpigmentation after 7 months of treatment with gefitinib. In the literature, we found no data regarding rapid pigmentation of hair due to treatment with any multi-target tyrosine kinase inhibitors. To our knowledge, this is the first case reporting both hair and eyebrow hyperpigmentation. We hypothesize the role of different mechanisms linked to rapid hair hyperpigmentation.Entities:
Keywords: Gefitinib; Hair hyperpigmentation; PRIDE complex; Reflectance confocal microscopy; oct4
Year: 2019 PMID: 32021862 PMCID: PMC6995969 DOI: 10.1159/000503758
Source DB: PubMed Journal: Skin Appendage Disord ISSN: 2296-9160